Thyrocare Technologies has announced its audited financial results for the quarter and year ended March 31, 2026, reporting a robust standalone revenue of ₹774.27 crore for the full fiscal year. Alongside these financial disclosures, the company revealed a series of strategic board appointments, the transition of its statutory auditors, and an investment of ₹5.50 crore in its subsidiary, Think Health Diagnostics, to support ongoing operations and capital expenditure.
Financial Performance Overview
For the financial year ended March 31, 2026, Thyrocare achieved a standalone profit for the period of ₹148.81 crore on revenue from operations of ₹774.27 crore. The Q4 standalone performance showed a profit of ₹43.58 crore. On a consolidated basis, the company delivered a total income of ₹846.03 crore for the year, with a consolidated profit for the period reaching ₹162.85 crore, underscoring the group’s operational growth.
Strategic Leadership and Board Changes
The company confirmed the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director, and CEO for a five-year term commencing May 4, 2027. Additionally, the Board has expanded its leadership team with the appointment of Mr. Uday Patel Kadam and Mr. Gaurav Verma as Non-Executive, Non-Independent Directors, effective May 8, 2026. These appointments follow the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, who stepped down due to other professional commitments.
Auditor Transition and Dividend
Thyrocare has announced the appointment of Price Waterhouse Chartered Accountants LLP as its new Statutory Auditors for a five-year term, following the completion of the tenure of M/s. M S K A & Associates LLP. Furthermore, the Board has recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26. When combined with the interim dividend already paid, the total dividend aggregates to ₹9.33 per equity share post-bonus adjustment.
Investment and Growth Initiatives
The Board approved an investment of up to ₹5.50 crore in Think Health Diagnostics Private Limited, a wholly owned subsidiary focused on building an affordable, high-volume diagnostics platform. Furthermore, the company has initiated an alteration of its Memorandum of Association to broaden its scope of activities within the healthcare and diagnostics ecosystem, allowing for greater involvement in allied services and digital health platforms.
Source: BSE
